Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Cetin Erol,
Liapis defined vulnerable plaque as a “future culprit plaque” and described its features: thin fibrous cap, large necrotic lipid core and inflammation. Then he stressed the importance of detection. Imaging technologies are perfect but they are invasive, expensive and not available everywhere. So biomarkers are an alternative option, there are many of them that could be used. Biomarkers predict natural history of carotid and cerebrovascular disease, predict perioperative risk and guide medical treatment. However, there is no gold standard among biomarkers.
By using High Definition Ultrasonography with computer assisted Plaque Analysis, active carotid plaques could be identified by measuring degree of stenosis, activity index and image based Risk Prediction Score. Homogenous and heterogeneous plaque differentiation should be done. Then he also mentioned the 3D construction of the plaque.
Fernandes first gave the general overview of renal artery stenosis, then why it should be treated. The reasons for treatment are: to control blood pressure and save renal function, then treatment choices are medical or interventional. Recent studies comparing medical and interventional therapies were summarised. According to the recent trend, medical treatment should be given as a first choice to these patients.
Narula drew the attention of the audience to the diversity between plaque rupture and the severity of stenosis. Also, no correlation has been found between the high risk plaque and the severity of stenosis. He stressed that more necrotic core means a thin fibrous cap, which can possibly predict major cardiovascular outcomes. Attenuation of the plaque seen by CT may herald the slow flow after PCI and Napkin Ring Type imaging shows the cholesterol burden. Stent implantation for a vulnerable plaque could end with no endothelisation. So a new type of stent would be preferable. Overall, the symposium was very useful for understanding the importance of the vulnerable plaque and the new developments in this issue.
Identification of vulnerable atherosclerotic plaques and impact on treatment decision